Ir para o conteúdo principal

Lexicon Pharmaceuticals (NASDAQ: LXRX) — Perfil da empresa, notícias e dados financeiros

Logo de Lexicon Pharmaceuticals
LXRX Lexicon Pharmaceuticals
Lexicon Pharmaceuticals primary media
Perfil da empresa

Lexicon Pharmaceuticals

Lexicon Pharmaceuticals (NASDAQ:LXRX) is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments for patients with diseases that are often overlooked or inadequately treated by existing therapies. Its operations span from the early-stage research and development of new drug candidates to the clinical trials necessary for regulatory approval. One of Lexicon's significant projects includes advancing treatments for diabetes, heart failure, and other metabolic disorders, aiming to address unmet medical needs and improve patient outcomes. The company's objectives involve pushing the boundaries of medical research to bring transformative therapies to the market, ensuring these innovations are accessible to the patients who need them most.

Resumo

Public USParticipação acionária
1995Ano de fundação
413Funcionários
The Woodlands, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
The Woodlands, US

Produtos e/ou serviços de Lexicon Pharmaceuticals

  • XERMELO (telotristat ethyl), an orally-delivered small molecule drug for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy.
  • Sotagliflozin, an investigational oral dual inhibitor of SGLT1 and SGLT2, aimed at treating heart failure and diabetes.
  • LX9211, a development-stage small molecule inhibiting AAK1 to potentially address neuropathic pain.
  • LX2761, a preclinical compound working as an SGLT1 inhibitor for diabetes but remains localized in the gastrointestinal tract.
  • Research on the role of SGLT inhibitors in renal and cardiovascular diseases, examining the broader therapeutic potential of these treatments.
  • Advancements in the understanding and application of small molecule drugs, focusing on novel treatments for chronic diseases.

equipe executiva do Lexicon Pharmaceuticals

  • Michael S. ExtonCEO & Director
  • Scott M. CoianteSenior VP & CFO
  • Brian T. CrumSenior VP, General Counsel & Secretary
  • Wendy E. McDermottSenior Vice President of Human Resources
  • Craig B. GranowitzSenior VP & Chief Medical Officer
  • Kristen L. AlexanderVice President of Finance & Accounting
  • Lisa M. DeFrancescoSenior Vice President of Investor Relations & Corporate Communications
  • Suma GopinathanSenior Vice President of Discovery
  • Rachel Yap MartensSenior VP & Chief Commercial Officer

Principais indicadores financeiros

Resultados divulgados pela Lexicon Pharmaceuticals, em USD.

Cap. de mercado
658,5 mi
Receita (TTM)
41,5 mi
P/L
—
LPA (diluído, TTM)
-0.2
Dividend yield
—
Margem de lucro
-147.4%
Receita e lucro anuais da Lexicon Pharmaceuticals
Fim do ano fiscalReceitaResultado operacionalLucro líquido
49,8 mi-48,9 mi-50,3 mi
31,1 mi-197,1 mi-200,4 mi
1,2 mi-171,8 mi-177,1 mi
139 mil-100,8 mi-101,9 mi